Prosecution Insights
Last updated: April 19, 2026

Celularity Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18056088 NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF DIBRINO, MARIANNE 1641 Non-Final OA Nov 16, 2022
17998199 PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19) VAN BUREN, LAUREN K 1638 Non-Final OA Nov 08, 2022
18048291 ENHANCED PLACENTAL STEM CELLS AND USES THEREOF TAKENAKA, RISA 1632 Final Rejection Oct 20, 2022
17619242 POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS BARRON, SEAN C 1653 Non-Final OA Dec 14, 2021
17309451 PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF TIWARI, VYOMA SHUBHAM 1634 Non-Final OA May 27, 2021
17302353 DEVICES AND METHODS FOR THAWING BIOLOGICAL MATERIAL KRCHA, MATTHEW D 1796 Final Rejection Apr 30, 2021

Managing Celularity Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month